CWM
BIB icon

Crowley Wealth Management’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Crowley Wealth Management’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,000
Closed -$50.7K – 409
2024
Q4 		$50.7K Buy
+1,000
New +$59.3K 0.04% 139

Other funds holding BIB

IMC Chicago
IMC Chicago Chicago, Illinois $278B AUM 44.93% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CIC
Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return
WWM
Westwood Wealth Management Los Angeles, California $255M AUM 54.97% 1-Year Est. Return
CIA
Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
PSFG
Park Square Financial Group Roswell, Georgia $13.2M AUM 23.63% 1-Year Est. Return

Crowley Wealth Management's BIB Position: Q1 2025 in Review

Crowley Wealth Management sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q1 2025, closing a stake of 1,000 shares — an estimated $50.7K sold.

Crowley Wealth Management first reported a position in BIB in Q4 2024 and held it in 1 quarter. The position peaked at $50.7K in Q4 2024. 23 funds tracked by Wall St. Rank hold BIB as of Q1 2025.

  • Crowley Wealth Management reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q1 2025 after selling out during the quarter.
  • Crowley Wealth Management sold 1,000 ProShares Ultra NASDAQ Biotechnology shares in Q1 2025, an estimated $50.7K.
  • Crowley Wealth Management first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2024 and held it in 1 quarter.
  • Crowley Wealth Management's ProShares Ultra NASDAQ Biotechnology position peaked at $50.7K in Q4 2024.
  • 23 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q1 2025.

Based on Crowley Wealth Management's 13F filing for Q1 2025, filed 16 Apr 2025.